[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Vinnikov et al., 2022 - Google Patents

Clinical applications of biological dosimetry in patients exposed to low dose radiation due to radiological, imaging or nuclear medicine procedures

Vinnikov et al., 2022

Document ID
1260361209233492822
Author
Vinnikov V
Belyakov O
Publication year
Publication venue
Seminars in Nuclear Medicine

External Links

Snippet

Radiation dosimetric biomarkers have found applications beyond radiation protection area and now are actively introduced into clinical practice. Cytogenetic assays appeared to be a valuable tool for individualized quantifying radiation effects in patients, with high capability …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493Steroids, e.g. cholesterol, testosterone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Similar Documents

Publication Publication Date Title
Hänscheid et al. Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days
May et al. Induction and repair of DNA double-strand breaks in blood lymphocytes of patients undergoing 18 F-FDG PET/CT examinations
Niemeijer et al. Study of 89Zr-pembrolizumab PET/CT in patients with advanced-stage non–small cell lung cancer
Chen et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy
Lassmann et al. In vivo formation of γ-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer
Dehdashti et al. Assessment of cellular proliferation in tumors by PET using 18F-ISO-1
Challapalli et al. 18F-ICMT-11, a caspase-3–specific PET tracer for apoptosis: biodistribution and radiation dosimetry
Liu et al. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor–selective tracer 11C-PD153035 in humans
Eberlein et al. DNA damage in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy
Eberlein et al. DNA damage in blood lymphocytes in patients after 177 Lu peptide receptor radionuclide therapy
Verburg et al. Dosimetry-guided high-activity 131 I therapy in patients with advanced differentiated thyroid carcinoma: initial experience
Geisel et al. DNA double-strand breaks as potential indicators for the biological effects of ionising radiation exposure from cardiac CT and conventional coronary angiography: a randomised, controlled study
Pathmanandavel et al. Evaluation of 177Lu-PSMA-617 SPECT/CT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)
John et al. 177Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy
Tolvanen et al. Safety, biodistribution, and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers
Torizuka et al. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET
Liu et al. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer
Livingston et al. Cytogenetic effects of radioiodine therapy: a 20-year follow-up study
Bozkurt et al. Sister chromatid exchanges in lymphocytes of nuclear medicine physicians
Grawé et al. Evaluation of the reticulocyte micronucleus assay in patients treated with radioiodine for thyroid cancer
Vinnikov et al. Clinical applications of biological dosimetry in patients exposed to low dose radiation due to radiological, imaging or nuclear medicine procedures
Taylor et al. Radiation-induced DNA damage and the relative biological effectiveness of 18F-FDG in wild-type mice
Erselcan et al. Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship
Sciuto et al. The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223 Ra: first in human study
Manning et al. Quantifying murine bone marrow and blood radiation dose response following 18F-FDG PET with DNA damage biomarkers